At present, the company has established extensive, in-depth and long-term cooperative relationships with many hospitals, and researches on multiple cancers such as lung cancer, colorectal cancer and gynecological tumors. The research direction covers the screening of early tumor markers and the prognosis. evaluation, tumor heterogeneity molecular classification and other fields, and

achieved fruitful results.

Genecast PD-L1

Indications: Solid tumors.

Strict QC

  • Genecast PD-L1® follows standard system by using Ventana PD-L1 monoclonal antibody kit from Roche.

  • Genecast PD-L1® uses human tonsil tissue as positive and negative control.

  • High sensitivity and good repeatability of testing.

Inspection requirements

Better sensitivity and specificity

  • Applicable population: all solid tumor patients

Specimen requirements

  • 10 unstained slides (Fresh Frozen, FFPE) from Department of pathology in the hospital. Use anti-stripping slices only.

  • Acceptable Samples: FFPE blocks of surgical tissue samples, puncture tissue samples, pleural effusion sediment samples, ascites sediment samples.

  • All samples must have corresponding official pathological reports.

Non-acceptable samples

  • Tissue sections already stained.

  • Tissue sections ruptured.

Detection TAT

  • Fresh Frozen,7days.

  • FFPE blocks 10  days.

Protein Detection Reports for PD-L1 / PD-1 and MMR

派蒂万 2.png

Detection Results:

派蒂万 3.png

Notes: +: positive; -: negative; + (<1%) (example): Positive (The number of positive cells in the total number of immune cells is less than 1%); /: No official standard, only for research.

Photos of results:

派蒂万 4.png

PD-L1 interpretation standards in the report:

派蒂万 5.png